Search Results - "Norman, R. A."

Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer by Smith, N. J., Barbachano, Y., Norman, A. R., Swift, R. I., Abulafi, A. M., Brown, G.

“…Background: Extramural vascular invasion (EMVI) is a poor prognostic feature in colorectal cancer. The accuracy of magnetic resonance imaging (MRI) in…”
Get full text

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer by Okines, A.F.C., Norman, A.R., McCloud, P., Kang, Y.-K., Cunningham, D.

“…The REAL-2 and ML17032 trials demonstrated that the oral fluoropyrimidine, capecitabine, is noninferior to 5-fluorouracil (5-FU) for overall survival (OS) and…”
Get full text

MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins? by BURTON, S, BROWN, G, DANIELS, I. R, NORMAN, A. R, MASON, B, CUNNINGHAM, D

“…Histopathological audit of positive circumferential resection margins (CRMs) can be used as a surrogate measure of the success of rectal cancer treatment. We…”
Get full text

Preoperative computed tomography staging of nonmetastatic colon cancer predicts outcome: implications for clinical trials by SMITH, N. J, BEES, N, BARBACHANO, Y, NORMAN, A. R, SWIFT, R. I, BROWN, G

“…Colon cancer patients routinely undergo preoperative computed tomography (CT) scanning, but local staging is thought to be inaccurate. We aimed to determine if…”
Get full text

Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours by O’Sullivan, J. M., Huddart, R. A., Norman, A. R., Nicholls, J., Dearnaley, D. P., Horwich, A.

“…Background: Bleomycin pulmonary toxicity (BPT) has been known since the early clinical trials of bleomycin in the 1960s. Postulated risk factors include…”
Get full text

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF by SUMPTER, K, HARPER-WYNNE, C, HILL, M, OATES, J, CUNNINGHAM, D, RAO, S, TEBBUTT, N, NORMAN, A. R, WARD, C, IVESON, T, NICOLSON, M, HICKISH, T

“…The purpose of the study was to establish the optimal dose of capecitabine (X) to be used within a multicentre, randomised study evaluating the potential roles…”
Get full text

Simple nutritional intervention in patients with advanced cancers of the gastrointestinal tract, non-small cell lung cancers or mesothelioma and weight loss receiving chemotherapy: a randomised controlled trial by Baldwin, C., Spiro, A., McGough, C., Norman, A. R., Gillbanks, A., Thomas, K., Cunningham, D., O'Brien, M., Andreyev, H. J. N.

“…Background:  Weight loss in patients with cancer is common and associated with a poorer survival and quality of life. Benefits from nutritional interventions…”
Get full text

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials by Maisey, N R, Norman, A R, Hill, A, Massey, A, Oates, J, Cunningham, D

“…In a multivariate analysis of 154 patients receiving chemotherapy, baseline CA19-9 was an independent prognostic factor for overall survival (OS) (HR 1.8; 95%…”
Get full text

Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis by Edwards, S M, Evans, D G R, Hope, Q, Norman, A R, Barbachano, Y, Bullock, S, Kote-Jarai, Z, Meitz, J, Falconer, A, Osin, P, Fisher, C, Guy, M, Jhavar, S G, Hall, A L, O'Brien, L T, Gehr-Swain, B N, Wilkinson, R A, Forrest, M S, Dearnaley, D P, Ardern-Jones, A T, Page, E C, Easton, D F, Eeles, R A

“…Background: The germline BRCA2 mutation is associated with increased prostate cancer (PrCa) risk. We have assessed survival in young PrCa cases with a germline…”
Get full text

Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? by ANDREYEV, H. J. N, NORMAN, A. R, OATES, J, CUNNINGHAM, D

“…The aim of this study was to examine whether weight loss at presentation, in patients who were to receive chemotherapy for gastrointestinal carcinomas,…”
Get full text

Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer by Negri, F.V., Wotherspoon, A., Cunningham, D., Norman, A.R., Chong, G., Ross, P.J.

“…Background:: Mucinous carcinoma of the colon and rectum (mucinous CRC) is a histological subtype of colorectal adenocarcinoma for which there is little data on…”
Get full text

Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases by Tebbutt, N C, Norman, A R, Cunningham, D, Hill, M E, Tait, D, Oates, J, Livingston, S, Andreyev, J

“…Background: The role of palliative resection of the primary tumour in patients who present with metastatic colorectal cancer is unclear. Aims: This study…”
Get full text

Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter “RASCAL” Study by Andreyev, H. Jervoise N., Norman, Andrew R., Clarke, Paul A., Cunningham, David, Oates, Jacqueline R.

“…Background: Kirsten ras (Ki-ras) gene mutations occur early in the progression of colorectal adenoma to carcinoma. The aim of this collaborative study was to…”
Get full text

Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma by Assersohn, L., Brown, G., Cunningham, D., Ward, C., Oates, J., Waters, J. S., Hill, M. E., Norman, A. R.

“…Background: The purpose of this study was to assess the efficacy and toxicity of irinotecan and 5-fluorouracil (5-FU) in primary refractory or relapsed locally…”
Get full text

model to test how ticks and louping ill virus can be controlled by treating red grouse with acaricide by PORTER, R, NORMAN, R. A, GILBERT, L

“…Ticks are the most important vectors of disease‐causing pathogens in Europe. In the U.K., Ixodes ricinus L. (Ixodida: Ixodidae) transmits louping ill virus…”
Get full text

How patients manage gastrointestinal symptoms after pelvic radiotherapy by Gami, B., Harrington, K., Blake, P., Dearnaley, D., Tait, D., Davies, J., Norman, A. R., Andreyev, H. J. N.

“…Summary Background : Approximately 13 000 patients undergo pelvic radiotherapy annually in the UK. It is not clear how frequently patients develop a permanent…”
Get full text

The impact of primary tumour origins in patients with advanced oesophageal, oesophago–gastric junction and gastric adenocarcinoma—individual patient data from 1775 patients in four randomised controlled trials by Chau, I., Norman, A.R., Cunningham, D., Oates, J., Hawkins, R., Iveson, T., Nicolson, M., Harper, P., Seymour, M., Hickish, T.

“…It is unclear if differential chemotherapy effects exist on overall survival (OS), response rate (RR) and toxicity depending on primary tumour origin…”
Get full text

Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials by Trumper, M., Ross, P.J., Cunningham, D., Norman, A.R., Hawkins, R., Seymour, M., Harper, P., Iveson, T., Nicolson, M., Hickish, T.

“…The aim of this study was to determine the benefits of chemotherapy for oesophago-gastric cancer (OGC) in patients 70 years and above (⩾70) in comparison to…”
Get full text

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer by Chau, I., Norman, A. R., Cunningham, D., Tait, D., Ross, P. J., Iveson, T., Hill, M., Hickish, T., Lofts, F., Jodrell, D., Webb, A., Oates, J. R.

“…Background: We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of protracted venous infusion (PVI) 5-fluorouracil…”
Get full text

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer by SAINI, A, NORMAN, A. R, ROSS, P. J, OATES, J, CUNNINGHAM, D, CHAU, I, HILL, M, TAIT, D, HICKISH, T, IVESON, T, LOFTS, F, JODRELL, D

“…We performed a multicentre randomised trial to compare the efficacy and toxicity of 12 weeks of 5-fluorouracil (5-FU) delivered by protracted intravenous…”
Get full text